Recurrent Febrile Episodes and Abdominal Pain

  • Per WekellEmail author
  • Stefan Berg
  • Anders Fasth


Familial Mediterranean fever (FMF) should be suspected in children with recurrent, fever attacks of short duration, 6 hours-3 days, associated with peritonitis, pleuritis and/or arthritis

FMF is most common in populations with eastern Mediterranean origin

FMF is considered an autosomal recessive disease, yet biallelic mutations are not always identified

Colchicine is the drug-of-choice that effectively prevents FMF attacks and amyloidosis

Secondary amyloidosis is the main long-term complication in untreated patients


Familial Mediterranean fever Colchicine MEFV 


  1. 1.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879–85.CrossRefGoogle Scholar
  2. 2.
    Yalcinkaya F, Ozen S, Ozcakar ZB, Aktay N, Cakar N, Duzova A, Kasapcopur O, Elhan AH, Doganay B, Ekim M, Kara N, Uncu N, Bakkaloglu A. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48(4):395–8.CrossRefGoogle Scholar
  3. 3.
    Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–53.CrossRefGoogle Scholar
  4. 4.
    Kasifoglu T, Cansu DU, Korkmaz C. Frequency of abdominal surgery in patients with familial Mediterranean fever. Intern Med. 2009;48(7):523–6.CrossRefGoogle Scholar
  5. 5.
    Heller H, Gafni J, Michaeli D, Shahin N, Sohar E, Ehrlich G, Karten I, Sokoloff L. The arthritis of familial Mediterranean fever (FMF). Arthritis Rheum. 1966;9(1):1–17.CrossRefGoogle Scholar
  6. 6.
    Azizi E, Fisher BK. Cutaneous manifestations of familial Mediterranean fever. Arch Dermatol. 1976;112(3):364–6.CrossRefGoogle Scholar
  7. 7.
    Ben-Chetrit E, Touitou I. Familial mediterranean fever in the world. Arthritis Rheum. 2009;61(10):1447–53.CrossRefGoogle Scholar
  8. 8.
    Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyturk M, Akar S, Tunca M, Hawkins PN. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45(6):746–50.CrossRefGoogle Scholar
  9. 9.
    Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–51.CrossRefGoogle Scholar
  10. 10.
    Henderson C, Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol. 2010;22(5):567–78.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302.PubMedGoogle Scholar
  12. 12.
    Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, Gafni J. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med. 1974;291(18):932–4.CrossRefGoogle Scholar
  13. 13.
    Gattorno M, SpringerLink (Online service). Familial Mediterranean Fever. Rare Diseases of the Immune System,.Google Scholar
  14. 14.
    Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol. 2007;13(1):38–40.CrossRefGoogle Scholar
  15. 15.
    Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2007.Google Scholar
  16. 16.
    Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–8.CrossRefGoogle Scholar
  17. 17.
    Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2013.Google Scholar
  18. 18.
    Stankovic Stojanovic K, Hentgen V, Fellahi S, Georgin-Lavialle S, Amselem S, Grateau G, Bastard JP, Steichen O. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: a study of 218 patients. Clin Biochem. 2017;50(4–5):206–9.CrossRefGoogle Scholar
  19. 19.
    Mor A, Gal R, Livneh A. Abdominal and digestive system associations of familial Mediterranean fever. Am J Gastroenterol. 2003;98(12):2594–604.CrossRefGoogle Scholar
  20. 20.
    Fukushima Y, Obara K, Hirata H, Sugiyama K, Fukuda T, Takabe K. Three Japanese patients (mother and two children) with familial Mediterranean fever associated with compound heterozygosity for L110P/E148Q/M694I and an autosomal true dominant inheritance pattern. Asian Pac J Allergy Immunol. 2013;31(4):325–9.CrossRefGoogle Scholar
  21. 21.
    Aldea A, Campistol JM, Arostegui JI, Rius J, Maso M, Vives J, Yague J. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet A. 2004;124A(1):67–73.CrossRefGoogle Scholar
  22. 22.
    Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, Soyturk M, Akar S, Pepys MB, Tunca M, Hawkins PN. The genetic basis of autosomal dominant familial Mediterranean fever. QJM. 2000;93(4):217–21.CrossRefGoogle Scholar
  23. 23.
    Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, Amselem S, Gershoni-Baruch R, Touitou I, Ben-Chetrit E. Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum. 2013;43(3):387–91.CrossRefGoogle Scholar
  24. 24.
    Langevitz P, Zemer D, Livneh A, Shemer J, Pras M. Protracted febrile myalgia in patients with familial Mediterranean fever. J Rheumatol. 1994;21(9):1708–9.PubMedGoogle Scholar
  25. 25.
    Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26(6):489–96.CrossRefGoogle Scholar
  26. 26.
    Mercan R, Turan A, Bitik B, Tufan A, Haznedaroglu S, Goker B. Rapid resolution of protracted febrile myalgia syndrome with anakinra: report of two cases. Mod Rheumatol. 2016;26(3):458–9.PubMedGoogle Scholar
  27. 27.
    Xu H, Yang J, Gao W, Li L, Li P, Zhang L, Gong YN, Peng X, Xi JJ, Chen S, Wang F, Shao F. Innate immune sensing of bacterial modifications of rho GTPases by the pyrin inflammasome. Nature. 2014;513(7517):237–41.CrossRefGoogle Scholar
  28. 28.
    Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, Kastner DL. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003;100(23):13501–6.CrossRefGoogle Scholar
  29. 29.
    Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, Katz SI, Kastner DL. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity. 2011;34(5):755–68.CrossRefGoogle Scholar
  30. 30.
    Akar S, Yuksel F, Tunca M, Soysal O, Solmaz D, Gerdan V, Celik A, Sen G, Onen F, Akkoc N. Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine. 2012;91(3):131–6.CrossRefGoogle Scholar
  31. 31.
    Twig G, Livneh A, Vivante A, Afek A, Shamiss A, Derazne E, Tzur D, Ben-Zvi I, Tirosh A, Barchana M, Shohat T, Golan E, Amital H. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis. 2014;73(4):704–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, NU Hospital GroupUddevallaSweden
  2. 2.Department of Pediatrics, Sahlgrenska Academy, University of GothenburgGothenburgSweden
  3. 3.Department of Rheumatology and Immunology, Queen Silvia Children’s HospitalGothenburgSweden

Personalised recommendations